Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.

Iwamoto N, Matsui A, Kazama H, Oura T

Diabetes therapy : research, treatment and education of diabetes and related disorders20 Dec 2017Cited by 3 (Europe PMC)

PMID29264713PMCIDPMC5801232DOI10.1007/s13300-017-0346-4PepBankPUB-29264713

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In Japanese patients with T2D receiving liraglutide, baseline beta-cell function showed no specific trend with HbA1c change.
In plain wordsIn Japanese patients receiving liraglutide, starting beta-cell function showed no clear trend with blood sugar marker changes across tertiles.
Peptide
Liraglutide
Outcome
No significant changeBaseline beta-cell function and HbA1c change
Study
n = 137
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg once daily · 52 weeksAs given in this study (human).
Source sentences
Summary
No specific trend was observed between baseline pancreatic β-cell function and changes in HbA1c or FBG.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
Report a problemFND-2926471302
02HumanObservational studyEfficacy outcome
In Japanese patients with T2D receiving liraglutide, baseline beta-cell function showed no specific trend with fasting blood glucose change.
In plain wordsIn Japanese patients receiving liraglutide, starting beta-cell function showed no clear trend with fasting blood sugar changes across tertiles.
Peptide
Liraglutide
Outcome
No significant changeBaseline beta-cell function and fasting blood glucose change
Study
n = 137
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg once daily · 52 weeksAs given in this study (human).
Source sentences
Summary
No specific trend was observed between baseline pancreatic β-cell function and changes in HbA1c or FBG.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
Report a problemFND-2926471304
03HumanObservational studyEfficacy outcome
In Japanese patients with T2D receiving liraglutide, mean postprandial glucose reductions were greatest in low beta-cell function tertiles.
In plain wordsIn Japanese patients receiving liraglutide, lower starting beta-cell function was linked to greater post-meal blood sugar reductions than higher function.
Peptide
Liraglutide
Outcome
DecreasePostprandial blood glucose reduction by beta-cell function
Study
n = 137
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg once daily · 52 weeksAs given in this study (human).
Source sentences
Summary
Reductions from baseline in mean PBG and excursion were greatest for patients in the low β-cell function tertiles.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
Report a problemFND-2926471306

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with T2D receiving dulaglutide, baseline beta-cell function showed no specific trend with HbA1c change.
In plain wordsIn Japanese patients receiving dulaglutide, starting beta-cell function showed no clear trend with blood sugar marker changes across tertiles.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBaseline beta-cell function and HbA1c change
Study
n = 280
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
No specific trend was observed between baseline pancreatic β-cell function and changes in HbA1c or FBG.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2926471301
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with T2D receiving dulaglutide, baseline beta-cell function showed no specific trend with fasting blood glucose change.
In plain wordsIn Japanese patients receiving dulaglutide, starting beta-cell function showed no clear trend with fasting blood sugar changes across tertiles.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBaseline beta-cell function and fasting blood glucose change
Study
n = 280
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
No specific trend was observed between baseline pancreatic β-cell function and changes in HbA1c or FBG.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2926471303
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with T2D receiving dulaglutide, mean postprandial glucose reductions were greatest in low beta-cell function tertiles.
In plain wordsIn Japanese patients receiving dulaglutide, lower starting beta-cell function was linked to greater post-meal blood sugar reductions than higher function.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePostprandial blood glucose reduction by beta-cell function
Study
n = 280
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Reductions from baseline in mean PBG and excursion were greatest for patients in the low β-cell function tertiles.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2926471305
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with T2D receiving dulaglutide, glucose excursion reductions were greatest in low beta-cell function tertiles.
In plain wordsIn Japanese patients receiving dulaglutide, lower starting beta-cell function was linked to greater reductions in glucose swings than higher function.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGlucose excursion reduction by beta-cell function
Study
n = 280
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Reductions from baseline in mean PBG and excursion were greatest for patients in the low β-cell function tertiles.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2926471307
08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Japanese patients with T2D treated with dulaglutide or liraglutide, reductions from baseline in mean postprandial glucose and glucose excursion were greatest in the low beta-cell function tertiles.
In plain wordsIn Japanese patients taking dulaglutide or liraglutide, post-meal glucose reductions were greatest in those with low starting beta-cell function.
Peptide
Liraglutide
Outcome
DecreaseGlucose excursion reduction by beta-cell function
Study
n: not reported in source
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Reductions from baseline in mean PBG and excursion were greatest for patients in the low β-cell function tertiles.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2926471308
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with T2D, body weight trends across beta-cell function parameters were inconsistent across treatment groups including dulaglutide.
In plain wordsIn Japanese patients, weight trends across starting beta-cell function were inconsistent across treatment groups including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
MixedBody weight change by beta-cell function
Study
n: not reported in source
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Inconsistent trends in body weight were observed across the treatment groups and β-cell function parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2926471309
10HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In Japanese patients with T2D, body weight trends across beta-cell function parameters were inconsistent across treatment groups including liraglutide.
In plain wordsIn Japanese patients, weight trends across starting beta-cell function were inconsistent across treatment groups including liraglutide.
Peptide
Liraglutide
Outcome
MixedBody weight change by beta-cell function
Study
n: not reported in source
Comparator
Higher baseline beta-cell function tertiles
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Inconsistent trends in body weight were observed across the treatment groups and β-cell function parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis investigated the relationship between baseline fasting pancreatic β-cell function and efficacy in Japanese patients with type 2 diabetes (T2D) treated with once-weekly dulaglutide 0.75 mg (dulaglutide) or once-daily liraglutide 0.9 mg (liraglutide) for up to 52 weeks.
Summary · context
Associations between these parameters and efficacy [defined by changes from baseline in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PBG), mean of all meals blood glucose excursion, and body weight]
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2926471310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01558271

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 492Mar 2012 to May 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 22 May 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC